FXS6837 – Talk Bio

Actionable Insights Powered by AI

Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal

Fosun Pharma; Sitala; FXS6837; immunology; license agreement; autoimmune diseases; biotech; pharmaceuticals; $670 million